Advances in the Effect of Donepezil in Cardiovascular Therapy

doi:10.12114/j.issn.1007-9572.2019.00.635

Abstract

Abstract: Alzheimer's disease（AD）is the main type of dementia，and the reduction of cholinergic neurons in the central nervous system is one of its important pathogenesis.Donepezil，as a highly selective and reversible cholinesterase inhibitor，improves cognitive function of dementia patients by elevating acetylcholine level in cortex through inhibiting cholinesterase，and now is one of the front-line treatment drugs for dementia.A large number of clinical studies have confirmed the effectiveness and safety of the clinical application of donepezil.Many AD patients also suffer from cardiovascular diseases，and current researches have indicated a therapeutic effect of donepezil on cardiovascular diseases.This article aims to review the current clinical use of donepezil and its effects on cardiovascular system，and to explore its mechanism.This article compares the effects of donepezil with galantamine and rivastigmine on cardiovascular diseases in order to provide feedback to guide the further use of donepezil in the clinical practice.

Key words: Donepezil, Cholinesterase inhibitor, Cardiovascular disease, Review

摘要： 阿尔茨海默病（AD）为痴呆的主要类型，中枢神经系统胆碱能神经元的减少是其重要的发病机制之一。多奈哌齐作为一种高选择性、可逆性的胆碱酯酶抑制剂，能够通过对胆碱酯酶的抑制提高大脑皮质中的胆碱水平，从而改善患者的认知功能，是当前临床上治疗痴呆的一线药物之一，已有大量的临床研究证实其临床应用的有效性及安全性。许多痴呆患者同时合并心血管疾病，近期有研究表明多奈哌齐对心血管系统疾病亦有治疗作用。本文旨在对多奈哌齐目前的临床使用及心血管系统作用进行综述，并探讨其作用机制，比较其与加兰他敏和利斯的明的心血管作用效果，以指导多奈哌齐在临床中的进一步运用。

关键词: 多奈哌齐, 胆碱酯酶抑制剂, 心血管疾病, 综述

LONG Jieni,XUE Yazhi,MA Yusheng, et al. Advances in the Effect of Donepezil in Cardiovascular Therapy　[J]. Chinese General Practice, 2020, 23(10): 1314-1317. DOI: 10.12114/j.issn.1007-9572.2019.00.635.
龙洁旎,薛雅芝,马煜盛等. 多奈哌齐的心血管治疗作用研究进展[J]. 中国全科医学, 2020, 23(10): 1314-1317. DOI: 10.12114/j.issn.1007-9572.2019.00.635.

References

［1］SHAJI K S，SIVAKUMAR P T，RAO G P．Clinical practice guidelines for management of dementia［J］．Indian J Psychiatry，2018，60（3）：312-328．DOI：10.4103/0019-5545.224472.
［2］赵静，苟云久，彭小兰，等．多奈哌齐治疗老年血管性痴呆的系统评价［J］．中国循证医学杂志，2011，11（11）：1280-1289.
ZHAO J，GOU Y J，PENG X L，et al．Donepezil in the treatment of senile vascular dementia：a systematic review［J］．Chin J Evid-based Med，2011，11（11）：1280-1289.
［3］朱琼，陈星星．阿尔茨海默病的流行病学调查及国内康复治疗现状分析［J］．中华物理医学与康复杂志，2017，39（11）：866-869．DOI：10.3760/cma.j.issn.0254-1424.2017.11.018.
ZHU Q，CHEN X X．An epedemic research and present situation of rehabilitation therapy on Alzheimer's disease in China［J］．Chin J Phys Med Rehabil，2017，39（11）：866-869．DOI：10.3760/cma.j.issn.0254-1424.2017.11.018.
［4］GO A S，MOZAFFARIAN D，ROGER V L，et al．Heart disease and stroke statistics—2013 update：a report from the American Heart Association［J］．Circulation，2013，127（1）：143-152．DOI：10.1161/CIR.0b013e318282ab8f.
［5］POBLADOR-PLOU B，CALDERóN-LARRA?AGA A，MARTA-MORENO J，et al．Comorbidity of dementia：a cross-sectional study of primary care older patients［J］．BMC Psychiatry，2014，14：84．DOI：10.1186/1471-244X-14-84.
［6］National Institute for Health and Clinical Excellence．Donepezil，galantamine，rivastigmine and memantine for the treatment of Alzheimer's disease［EB/OL］．（2018-12-25）．http://www.nice.org.uk/guidance/TA217.
［7］TAKAYA T，OKAMOTO M，YODO K，et al．Torsades de pointes with QT prolongation related to donepezil use［J］．J Cardiol，2009，54（3）：507-511．DOI：10.1016/j.jjcc.2009.03.011.
［8］GILL S S，ANDERSON G M，FISCHER H D，et al．Syncope and its' consequences in patients with dementia receiving cholinesterase inhibitors：a population based cohort study［J］．Arch Intern Med，2009，169（9）：867-873．DOI：10.1001/archinternmed.2009.43.
［9］SEGAL-GIDAN F，CHERRY D，JONES R，et al．Alzheimer's disease management guideline：update 2008［J］．Alzheimers Dement，2011，7（3）：e51-59．DOI：10.1016/j.jalz.2010.07.005.
［10］BORDIER P，GARRIGUE S，LANUSSE S，et al．Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease［J］．CNS Drugs，2006，20（5）：411-417.
［11］ISIK A T，YILDIZ G B，BOZOGLU E，et al．Cardiac safety of Donepezil in elderly patients with Alzheimer disease［J］．Intern Med，2012，51（6）：575-578.
［12］SABBAGH M，HAN S，KIM S，et al．Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimer's disease in the Asia-Pacific Region［J］．Dement Geriatr Cogn Dis Extra，2016，6（3）：382-395.
［13］SATO K，URBANO R，YU C，et al．The effect of donepezil treatment on cardiovascular mortality［J］．Clin Pharmacol Ther，2010，88（3）：335-358．DOI：10.1038/clpt.2010.98.
［14］NORDSTR?M P，RELIGA D，WIMO A，et al．The use of cholinesterase inhibitors and the risk of myocardial infarction and death：a nationwide cohort study in subjects with Alzheimer's disease［J］．Eur Heart J，2013，34（33）：2585-2591．DOI：10.1093/eurheartj/eht182.
［15］LIN Y T，WU P H，CHEN C S，et al．Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementia［J］．Sci Rep，2016，6：29266．DOI：10.1038/srep29266.
［16］WU P H，LIN Y T，HSU P C，et al．Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia［J］．Sci Rep，2015，5：15451．DOI：10.1038/srep15451.
［17］KUBO T，SATO T，NOGUCHI T，et al．Influences of donepezil on cardiovascular system—possible therapeutic benefits for heart failure—Donepezil Cardiac Test Registry（DOCTER）study［J］．J Cardiovasc Pharmacol，2012，60（3）：310-314.
［18］LI M，ZHENG C，KAWADA T，et al．Donepezil markedly improved long-term survival in rats with chronic heart failure after extensive myocardial infarction［J］．Circ J，2013，77（10）：2519-2525.
［19］LI M，ZHENG C，KAWADA T，et al．Adding the acetylcholinesterase inhibitor，donepezil，to losartan treatment markedly improves long-term survival in rats with chronic heart failure［J］．Eur J Heart Fail，2014，16（10）：1056-1065．DOI：10.1002/ejhf.164.
［20］YUAN X，TENG X，WANG Y，et al．Recipient treatment with acetylcholinesterase inhibitor donepezil attenuates primary graft failure in rats through inhibiting post-transplantational donor heart ischemia/reperfusion injury［J］．Eur J Cardiothorac Surg，2017，53（2）：400-408．DOI：10.1093/ejcts/ezx289.
［21］王振，惠杰．迷走神经刺激与心力衰竭［J］．心血管病学进展，2016，37（2）：197-201．DOI：10.16806/j.cnki.issn.1004-3934.2016.02.000.
WANG Z，HUI J．Vagus nerve stimulation and heart failure［J］．Adv Cardiovasc Dis，2016，37（2）：197-201．DOI：10.16806/j.cnki.issn.1004-3934.2016.02.000.
［22］DE JONGE W J，VAN DER ZANDEN E P，THE F O，et al．Stimulation of the vagus nerve attenuates macrophage activation by activating the JAK2-STAT3 signaling pathway［J］．Nat Immunol，2005，6（8）：844-845.
［23］INANAGA K，ICHIKI T，MIYAZAKI R，et al．Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice［J］．Atherosclerosis，2010，213（1）：52-58．DOI：10.1016/j.atherosclerosis.2010.07.027.
［24］PAVLOV V A，TRACEY K J．Controlling inflammation：the cholinergic anti-inflammatory pathway［J］．Biochem Soc Trans，2006，34（6）：1037-1040.
［25］CAI H，HARRISON D G．Endothelial dysfunction in cardiovascular diseases：the role of oxidant stress［J］．Circ Res，2000，87（10）：840-844.
［26］WILCOCK G K，LILIENFELD S，GAENS E．Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease：multicentre randomized controlled trial［J］．BMJ，2000，321（7274）：1445-1449.
［27］NORDSTR?M P，RELIGA D，WIMO A，et al．The use of cholinesterase inhibitors and the risk of myocardial infarction and death：a nationwide cohort study in subjects with Alzheimer's disease［J］．Eur Heart J，2013，34（33）：2585-2591．DOI：10.1093/eurheartj/eht182.
［28］KAUSHIK V，SMITH S T，MIKOBI E，et al．Acetylcholinesterase inhibitors：beneficial effects on comorbidities in patients with Alzheimer's disease［J］．Am J Alzheimers Dis Other Demen，2018，33（2）：73-85．DOI：10.1177/1533317517734352.

[1]	YU Xinyan, ZHAO Jun, ZHAO Xiaoye, JIANG Qingru, CHEN Yatian, WANG Yan, ZHANG Haicheng. Application of Mobile Smart Healthcare in the Prevention and Control of Cardiovascular Diseases in Elderly Patients with Chronic Diseases in Primary Care [J]. Chinese General Practice, 2023, 26(33): 4167-4172.
[2]	MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou. Interpretation of Report on Cardiovascular Health and Diseases in China 2022 [J]. Chinese General Practice, 2023, 26(32): 3975-3994.
[3]	PAN Yaojia, WANG Weiqiang, YI Weizhuo, GAO Bing, FU Fanglin, HAN Zheng, SUN Meng, DONG Yaqin, GU Huaicong. Relationship between Triglyceride-glucose Index and Risk of Cardiovascular Diseases in Middle-aged Obese Residents of Different Genders [J]. Chinese General Practice, 2023, 26(29): 3628-3635.
[4]	HE Rong, ZHANG Li, LI Peng, ZHANG Xiaoling, ZHANG Guo, ZANG Yiran, WU Shouling, SUN Lixia. Immediate Effects of Aerobic Exercise on Arterial Stiffness in a Male Population with Different Blood Glucose Levels [J]. Chinese General Practice, 2023, 26(24): 2997-3004.
[5]	CHEN Ruimin, LIU Fang, TAN Hong, HAN Shufang, CHEN Yingjian, SU Congcong. Effects of Dapagliflozin on the Expression of MicroRNA-423-5p and Cardiac Function in Patients with Type 2 Diabetes Mellitus and Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(14): 1733-1738.
[6]	YUE Bocheng, HOU Qiqi, HAN Quanle, YANG Bo, WU Zheng, WU Jianmei, CHEN Shuohua, WU Shouling, LI Kangbo. Effect of Atrial Fibrillation on the Risk of New-onset Myocardial Infarction in Hypertensive Population [J]. Chinese General Practice, 2023, 26(14): 1739-1744.
[7]	CAI Ming, WANG Liyan, YANG Ruoyu, LIANG Leichao, YANG Yuanyuan, JIA Shihao, CHEN Ruiyi, REN Yu, LIU Qianle, HU Jingyun. Short-term High-intensity Interval Training Reduces the Accumulation of Advanced Glycation End Products and the Risk of Cardiovascular Disease in Normal Weight Obese Female University Students: a Randomized Controlled Trial [J]. Chinese General Practice, 2023, 26(12): 1472-1478.
[8]	ZHANG Ning, HOU Ming, MEI Bo, JIN Weitao, TAN Xiong, YANG Mingchuan, WANG Liang, LIU Yong, LAI Yinglong. Hybrid Ablation: a Future Development Trend in the Management of Atrial Fibrillation [J]. Chinese General Practice, 2023, 26(09): 1136-1145.
[9]	LIU Taotao, LI Tianrong, WANG Xue, CHEN Jiameng, SHUAI Zhiqin, LI Lisheng, XU Shangfu. Nanoparticle- and Exosome-based Targeted Drug Delivery Systems Used in the Diagnosis and Treatment of Atherosclerosis: Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(08): 903-910.
[10]	ZHANG Haicheng, YU Xinyan, WANG Hongyu, XUE Tao, LIAO Xiaoyang, FAN Yongmei, ZHANG Qinghong. Discussion on the Difficulties and Bottlenecks in the Management of Remote ECG-based Screening for Cardiovascular Disease Risk in Hierarchical Diagnosis and Treatment [J]. Chinese General Practice, 2023, 26(05): 525-531.
[11]	WU Changyong, BAO Suli, XU Fei, PENG Yunzhu. Latest Advances in Exercise-induced Autophagy in Improving Cardiovascular Disease Prognosis [J]. Chinese General Practice, 2023, 26(05): 629-634.
[12]	WANG Zhe, ZHAO Haibin, WANG Guoliang, MA Xiaojuan, YIN Huijun. Complete Revascularization for Acute Myocardial Infarction and Multivessel Disease: an Overview of Systematic Reviews [J]. Chinese General Practice, 2023, 26(02): 142-153.
[13]	TANG Zhaoyun, HE Yang, CHEN Cong, YANG Xiaodan, WU Xinhua, LIU Hong. Risk Assessment of Ischemic Cardiovascular Disease in Rural Naxi Population in Low-to-high Altitudes [J]. Chinese General Practice, 2022, 25(36): 4522-4527.
[14]	SUN Zhenzhen, LIU Huanhuan, CHEN Kaining, LOU Qingqing. New Advances in the Value of the Normal Urinary Albumin as a Predictor of Multiple Diseases [J]. Chinese General Practice, 2022, 25(33): 4191-4195.
[15]	LIAO Jia, WEI Shuangyi, LIU Gang. Overview and Trends of Premature Deaths Due to Four Major Noncommunicable Diseases among Shenzhen Permanent Residents, 2014-2020 [J]. Chinese General Practice, 2022, 25(32): 4085-4090.